KES-0001 is under clinical development by Kesios Therapeutics and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData, Phase II drugs for Refractory Multiple Myeloma have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how KES-0001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

KES-0001 overview

DTP-3 (KES-0001) was under development for the treatment of relapsed or refractory multiple myeloma, diffuse large b-cell lymphoma, primary mediastinal b-cell lymphoma, high-grade b-cell lymphoma. DTP-3 is a tripeptide administered intravenously. The therapeutic candidate disrupts GADD45beta (growth arrest and DNA damage-inducible protein) and MKK7 (mitogen-activated protein kinase kinase 7) complex.

Kesios Therapeutics overview

Kesios Therapeutics Limited, an oncology drug discovery company that develops small molecule drugs for haematological malignancies. The company is headquartered in United Kingdom.

For a complete picture of KES-0001’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.